Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for JAMES BLOOM
70.25
-0.98 (-1.38%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 69.81 - 72.10
52 week 38.49 - 74.96
Open 71.68
Vol / Avg. 6.22M/1.32M
Mkt cap 10.55B
P/E     -
Div/yield     -
EPS -0.21
Shares 148.07M
Beta 1.11
Inst. own 97%
Mar 3, 2015
Alkermes Plc at Cowen Health Care Conference - 10:40AM EST - Add to calendar
Mar 2, 2015
Alkermes Plc Investor Day - 4:00PM EST - Add to calendar
Feb 24, 2015
Q4 2014 Alkermes Plc Earnings Release
Feb 24, 2015
Q4 2014 Alkermes Plc Earnings Call - Webcast
Feb 11, 2015
Alkermes Plc at Leerink Global Healthcare Conference
Feb 10, 2015
Alkermes Plc at Biotechnology Industry Organization CEO & Investor Conference
Jan 13, 2015
Alkermes Plc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2015
Alkermes Plc at JPMorgan Healthcare Conference
Dec 2, 2014
Alkermes Plc at NASDAQ OMX Investor Program - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 17.42% -4.86%
Operating margin -8.96% -14.08%
EBITD margin - 1.77%
Return on average assets 6.51% -1.72%
Return on average equity 8.96% -2.44%
Employees 1,250 -
CDP Score - -

Address

Connaught House 1 Burlington Road, Dublin 4
DUBLIN,
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes PLC, is an Ireland-based biopharmaceutical company. The Company is positioned to be an engine of treatments for clinical conditions specifically focused on central nervous system disorders, such as schizophrenia, addiction and depression. The products are based on science and technology that provide treatment options for patients with chronic diseases. The Company�s productline includes: Risperdal Consta, a long-acting injectable medication for treatment of Bipolar I Disorder; Invega Sustenna, used for treatment of schizophrenia and schizoaffective disorder; Vivitrol, a prescription injectable medicine used to treat alcohol dependence and prevent relapse to opioid dependence after opioid detox; Bydureon, injectable prescription to treat type 2 diabetes mellitus; Ampyra, oral medication for treatment of multiple sclerosis; Xeplion, treatment of schizophrenia in adult patients, and Fampyra, for treatment of multiple sclerosis.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane Cooke President
Age: 51
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 56
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President, Corporate Communications
Age: 38
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters